Dr. James Mier, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Indiana University / Bloomington

  Medical School, 1973

• Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling, 2010-08-10

• The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared to Rapamycin in Renal Cell Carcinoma, 2010-07-06

• Novel drugs that target the metabolic reprogramming in renal cell cancer, 2016-07-13

• Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+myeloid derived suppressor cells, 2013-03-05

• The High-Dose Aldesleukin "Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma, 2014-11-25

• Clinical utility of a blood-based BRAF V600E mutation assay in melanoma, 2014-10-15

• Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for TargetingDe NovoResistance Using BH3 Mimetics, 2014-07-01

• CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors, 2019-07-31

• Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference, 2009-05-15

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts National Harbor, MD, USA. 9-13 November 2016, 2016-12-08

• Retraction Note to: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells, 2021-06-11

• An inexpensive, specific and highly sensitive protocol to detect the BrafV600Emutation in melanoma tumor biopsies and blood, 2010-08-26

• Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma, 2021-06-15

• Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression, 2011-04-29

• Differential modulatory effects of GSK-3ß and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma, 2011-09-19